Business Context and Reporting Period
This Form 8-K Current Report was filed by Atara Biotherapeutics, Inc. on October 12, 2015. The filing discloses the execution of amended and restated employment agreements with four key executives: Isaac Ciechanover, M.D. (CEO), John McGrath (CFO), Christopher Haqq, M.D., Ph.D. (CMO), and Mitchall Clark (Chief Regulatory and Quality Assurance Officer).
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
Executive Base Salaries
- Isaac Ciechanover, M.D. (CEO): $525,000 (plus a monthly payment of $4,800)
- John McGrath (CFO): $345,000
- Christopher Haqq, M.D., Ph.D. (CMO): $400,000
- Mitchall Clark (Chief Regulatory and Quality Assurance Officer): $300,000
Target Annual Bonuses
- CEO: Up to 55% of base salary
- CFO, CMO, and Chief Regulatory Officer: Up to 40% of base salary
Material Changes
The Restated Employment Agreements supersede and replace the executives' current employment agreements. The primary material changes involve the formalization of base salaries, target bonus percentages, and specific severance and equity acceleration provisions triggered by termination without "Cause" or resignation for "Good Reason," particularly in the context of a "Change in Control."
Outlook, Risks, and Contingencies
Severance and Change in Control Provisions:
- Standard Termination (Outside Change in Control Window): Executives are entitled to 9 months of base salary (or a lump sum for the CEO), 9 months of COBRA premiums (12 months for the CEO), and limited equity acceleration (6 months for CEO, 3 months for CMO).
- Termination Near Change in Control (3 months prior to 12 months post): Executives receive a lump sum equal to one year of base salary (1.5x for CEO), 12 months of COBRA premiums (18 months for CEO), a lump sum equal to the Target Bonus (1.5x for CEO), and full acceleration of time-based equity awards.
Conditions: Severance payments are contingent upon the executive executing and not revoking a general release of claims. Bonus payments are discretionary and based on objectives determined by the Board or Compensation Committee.
Key Facts for Investor Verification
- Verify the total potential cash outflow for severance in a Change in Control scenario, noting the CEO's 1.5x multiplier on salary and bonus.
- Confirm the impact of full equity acceleration on the company's dilution in the event of a Change in Control.
- Review the attached Exhibits 10.1 through 10.4 for the complete legal definitions of "Cause," "Good Reason," and "Change in Control."
- Note that the filing does not provide updated financial statements or guidance on the company's operational performance.